Edgewise Therapeutics, Inc.
18
2
7
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 18 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
11%
1 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
Role: lead
Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
Role: lead
A Study to Evaluate EDG-7500 in People With Renal Impairment
Role: lead
A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment
Role: lead
A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults
Role: lead
A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
Role: lead
A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)
Role: lead
Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy
Role: lead
A Study of EDG-15400 in Healthy Adults
Role: lead
A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy
Role: lead
Defining Endpoints in Becker Muscular Dystrophy
Role: collaborator
A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500
Role: lead
A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers
Role: lead
A Study of EDG-7500 in Healthy Adults
Role: lead
Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers
Role: lead
Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle Diseases
Role: collaborator
A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling
Role: lead
A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults
Role: lead
All 18 trials loaded